ANDA 90317, held by OneSource Specialty. Metoprolol Tartrate.
As of Nov 22, 2026, ANDA 90317 (Metoprolol Tartrate), held by OneSource Specialty, was first approved by FDA on Apr 19, 2010, with 5 approved supplements and 0 published complete response letters.
Metoprolol Tartrate Injection, USP is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. Metoprolol Tartrate Injection, USP is a betaadrenergic receptor inhibitor indicated for the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 19, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metoprolol Tartrate1MG/ML ยท injectable;injection | Metoprolol Tartrate | Discontinued |
| Mar 18, 2026 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Mar 18, 2026 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Mar 18, 2026 | Supplement 13Labeling ยท Standard review | Approved | None posted |
| Jan 21, 2016 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Jan 21, 2016 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Apr 19, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters